GlassScriptPhysician profile
Diane D Nightengale
NPI 1265423149
$13,755.34
in general payments reported to CMS, 2019-2025
56 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $1,360 · 2021: $2,346 · 2022: $2,654 · 2023: $2,004 · 2024: $2,412 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,626.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,501.76 | 2020-2025 | |
| Lilly USA, LLC | $1,342.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,294.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,286.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $950.59 | 2019-2025 | |
| Amgen INC. | $923.10 | 2019-2025 | Evenity, Prolia, Otezla |
| Astellas Pharma US INC | $677.65 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $556.76 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $519.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $439.37 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.94 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $335.43 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $254.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $245.36 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.18 | 2019-2025 | Jardiance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Nightengale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.